Misplaced Pages

Ethylamphetamine
INN: Etilamfetamine

Clinical data
Trade names	Apetinil; Adiparthrol
Other names	Etilamfetamine; Ethylamphetamine; N-Ethylamphetamine; PAL-99; PAL99
Routes of administration	Oral, sublingual, insufflated, inhaled (vaporized), intravenous, rectal
ATC code	A08AA06 (WHO)
Legal status
Legal status	BR: Class B1 (Psychoactive drugs) CA: Schedule I DE: Anlage II (Authorized trade only, not prescriptible) UK: Class C US: Schedule I
Pharmacokinetic data
Metabolism	Hepatic (N-dealkylation, others)
Metabolites	Amphetamine
Excretion	Urine (5–18% as amphetamine)
Identifiers
IUPAC name N-Ethyl-1-phenyl-propan-2-amine
CAS Number	457-87-4
PubChem CID	9982
ChemSpider	9588
UNII	022YON1XMX
KEGG	D07114
ChEMBL	ChEMBL276443
CompTox Dashboard (EPA)	DTXSID10860359
ECHA InfoCard	100.230.711
Chemical and physical data
Formula	C11H17N
Molar mass	163.264 g·mol
3D model (JSmol)	Interactive image
SMILES N(C(Cc1ccccc1)C)CC
InChI InChI=1S/C11H17N/c1-3-12-10(2)9-11-7-5-4-6-8-11/h4-8,10,12H,3,9H2,1-2H3 Key:YAGBSNMZQKEFCO-UHFFFAOYSA-N
(verify)

Etilamfetamine, also known as N-ethylamphetamine and formerly sold under the brand names Apetinil and Adiparthrol, is a stimulant drug of the amphetamine family. It was invented in the early 20th century and was subsequently used as an anorectic or appetite suppressant in the 1950s, but was not as commonly used as other amphetamines such as amphetamine, methamphetamine, and benzphetamine, and was largely discontinued once newer drugs such as phenmetrazine were introduced.

Pharmacology

Pharmacodynamics

Monoamine releasing agent

Ethylamphetamine is a potent dopamine releasing agent (DRA) in vitro, with an EC₅₀Tooltip half-maximal effective concentration of 88.5 nM. This is about 10-fold lower than the EC₅₀ of dextroamphetamine. The EC₅₀ values of ethylamphetamine for induction of norepinephrine and serotonin release were not reported. However, the EC₅₀ values of its dextrorotatory enantiomer dextroethylamphetamine have been reported and were 44.1 nM, 28.8 nM, and 333 nM for norepinephrine, dopamine, and serotonin, respectively. Hence, dextroethylamphetamine acts as a norepinephrine–dopamine releasing agent (NDRA) with weak effects on serotonin.

In terms of structure–activity relationships, the potency of amphetamines as dopamine releasing agents and reuptake inhibitors decreases with increasing N-alkyl chain length. That is, the order of potency of N-alkylated amphetamines is as follows: amphetamine > methamphetamine > ethylamphetamine > propylamphetamine > butylamphetamine. Propylamphetamine is a weak dopamine reuptake inhibitor rather than releaser, whereas butylamphetamine is completely inactive as a dopamine releaser or reuptake inhibitor. The same relationship, for monoamine release and reuptake inhibition generally, has been shown with 4-methylamphetamine and its N-alkylated derivatives like 4-methylmethamphetamine and so forth.

Other actions

Ethylamphetamine is inactive as an agonist of the mouse and human trace amine-associated receptor 1 (TAAR1), whereas findings in the case of the rat TAAR1 are conflicting. In one study, its K_i was 2,500 nM and its EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) was 880 nM (62%) at the rat TAAR1 (i.e., it was a partial agonist), whereas its K_i and/or EC₅₀ values at the mouse and human TAAR1 were >10,000 nM. In another study however, ethylamphetamine showed very little capacity to activate the rat TAAR1.

Pharmacokinetics

Ethylamphetamine can be N-dealkylated into amphetamine (5–18% excreted in urine after 24 hours). As such, amphetamine may contribute to its effects in vivo.

Chemistry

The molecular structure of ethylamphetamine is analogous to methamphetamine, with an ethyl group in place of the methyl group. It can also be considered a substituted amphetamine, with an ethyl group on the amphetamine backbone.

Analogues of ethylamphetamine include amphetamine, methamphetamine, propylamphetamine, isopropylamphetamine, butylamphetamine, fenfluramine (3-trifluoromethyl-N-ethylamphetamine), dimethylamphetamine, and 3-fluoroethamphetamine (3-fluoro-N-ethylamphetamine), among others.

Society and culture

Recreational use

Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though it is of lower potency.

Notes

1. Amphetamine is a substituted phenethylamine with a methyl group at R position.
2. The ethyl group of ethylamphetamine is at R position, hence the name N-ethylamphetamine.
3. Ethylamphetamine is structurally similar to N-methylamphetamine (methamphetamine), the ethyl group being replaced in methamphetamine with a methyl group.

References

1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
2. ^ Beckett AH, Shenoy EV (October 1973). "The effect of N-alkyl chain length of stereochemistry on the absorption, metabolism and during excretion of N-alkylamphetamines in man". J Pharm Pharmacol. 25 (10): 793–799. doi:10.1111/j.2042-7158.1973.tb09943.x. PMID 4151673.
3. Junet R (October 1956). "L'éthylamphétamine dans le traitement de l'obésité" [Ethylamphetamine in the treatment of obesity]. Praxis. 45 (43): 986–988. PMID 13389142.
4. ^ Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug Alcohol Depend. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
5. ^ Fitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, Baumann MH, Fantegrossi WE (March 2024). "Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones". Neuropharmacology. 245: 109827. doi:10.1016/j.neuropharm.2023.109827. PMC 10842458. PMID 38154512.
6. ^ Nicole, Lauren (2022). "In vivo Structure-Activity Relationships of Substituted Amphetamines and Substituted Cathinones". ProQuest. Retrieved 5 December 2024. FIGURE 2-6: Release: Effects of the specified test drug on monoamine release by DAT (red circles), NET (blue squares), and SERT (black traingles) in rat brain tissue. EC50 values determined for the drug indicated within the panel.
7. Solis E, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, Eltit JM, Glennon RA, Negus SS, Baumann MH (September 2017). "N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability". Neuropsychopharmacology. 42 (10): 1950–1961. doi:10.1038/npp.2017.98. PMC 5561352. PMID 28530234.
8. Sakloth, Farhana (11 December 2015). Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action. VCU Scholars Compass (Thesis). doi:10.25772/AY8R-PW77. Retrieved 24 November 2024.
9. Forsyth, Andrea N (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines". ScholarWorks@UNO. Retrieved 4 November 2024.
10. ^ Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken : Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W.
11. ^ Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707. S2CID 15573624.
12. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (March 2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
13. ^ Partilla JS, Dersch CM, Baumann MH, Carroll FI, Rothman RB (1999). "Profiling CNS Stimulants with a High-Throughput Assay for Biogenic Amine Transporter Substractes". Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc (PDF). NIDA Res Monogr. Vol. 180. pp. 1–476 (252). PMID 11680410. RESULTS. Methamphetamine and amphetamine potently released NE (IC50s = 14.3 and 7.0 nM) and DA (IC50s = 40.4 nM and 24.8 nM), and were much less potent releasers of 5-HT (IC50s = 740 nM and 1765 nM).
14. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–1203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943.
15. Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". European Journal of Pharmacology. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
16. Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
17. ^ Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601.
18. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (December 2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Mol Pharmacol. 60 (6): 1181–1188. doi:10.1124/mol.60.6.1181. PMID 11723224.

• Anorectics
• Norepinephrine-dopamine releasing agents
• Stimulants
• Substituted amphetamines
• TAAR1 agonists